EP31670 + ruxolitinib

**EP31670 + ruxolitinib** is an investigational combination drug therapy comprising EP31670 (a dual inhibitor of BET and CBP/p300 proteins) and ruxolitinib (a potent Janus kinase inhibitor targeting JAK1 and JAK2). EP31670 is a first-in-class small molecule designed to simultaneously inhibit the bromodomain and extraterminal (BET) family proteins and the CREB-binding protein (CBP)/p300 proteins, all of which are involved in epigenetic regulation of gene transcription and cancer cell survival[5][9]. Ruxolitinib blocks cytokine and growth factor signaling pathways essential for abnormal proliferation in myeloproliferative neoplasms[2][4][6]. The combination aims to provide deeper and more durable clinical benefit by stacking distinct mechanisms: epigenetic reprogramming by BET/CBP/p300 inhibition (EP31670) and immune/cytokine suppression by JAK inhibition (ruxolitinib)[5][9][1]. Clinical development is focused on advanced solid tumors and hematological malignancies, including myelofibrosis[1][5].

Brand names

Jakavi

Other names

EP31670EP-31670EP 31670NEO2734NEO-2734NEO 2734ruxolitinib